GENE ONLINE|News &
Day 4 ASCO 2021 Roundup: Immunotherapy Candidates Show Promise in Early Studies
The fourth day of the ASCO 2021 virtual annual meeting featured clinical trial data of some promising immunotherapy candidates.
Oncolytic Viral Therapy Shows Promising Results in Fighting T-cell Lymphoma. Joselle Cook, MBBS, from the Mayo Clinic presented the results of Phase 1 clinical trial testing the effects of a novel oncolytic virotherapy against hematological malignancies.
It's free! Log in now to read
LATEST
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
